NEW YORK – Biomedical software startup BostonGene on Tuesday announced a research collaboration with Thomas Jefferson University and its Sidney Kimmel Cancer Center-Jefferson Health affiliate to study the molecular, cellular, and immunologic profiles of patients with squamous cell carcinoma of the head and neck who are treated with two existing drugs.